In North America and Europe, our impact is achieved through targeting health areas in deep need of investment. We measure women, children and adolescent users reached.

From research through to venture funding and post-acquisition, women’s, children’s and adolescents’ health innovations have historically received only a fraction of investment capital compared to those focused on men’s health. Furthermore, due to historical restrictions on women taking part in clinical studies during their childbearing years, studies have been heavily weighted towards adult male patients which has led to a male centric health system. Clinical trials on children are also rare, often leaving medical professionals with no option but to use medicines off-label and to rely on poorly tailored medical devices and diagnostic tests to test and treat children. As a result, health inequalities persist between men and women and between men and children. These are further compounded when considering other aspects of diversity such as the socioeconomic determinants of health and racism and further multiplied when considering health outcomes in low and middle income countries (LMICs) relative to wealthier countries, especially those in sub-Saharan Africa.

To achieve impact, we invest in companies that have CEOs with an innate desire to scale their solutions globally and that are commercializing resilient technologies designed to reach millions of people worldwide profitably. All the companies we invest in will have growth objectives in LMICs, tied to impact targets, in parallel to a growth strategy in North American and European markets. Our role is to be a key connector and enabler for our companies so that we may unlock their ambitions for inclusive global growth.